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Abstract. Nitric oxide (NO) is involved in several physiological processes, such as the control 
of vascular tone, the immune response and the wound healing process. Thus, there is a great 
interest in the development of NO-releasing drugs and in matrices which are able to stabilize 
and release NO locally in different tissues. Thiols, such as glutathione (GSH), are ready 
nitrosated to form the NO donors S-nitrosothiols (RSNOs). In this work, GSH, a precursor of 
the NO donor S-nitrosoglutathione (GSNO), was encapsulated into a mucoadhesive 
combination of alginate/chitosan nanoparticles. The encapsulated GSH was nitrosated in the 
alginate/chitosan nanoparticles by adding sodium nitrite, leading to the formation of 
encapsulated GSNO. The cytotoxicity characterization of the nanoparticles containing either 
GSH or GSNO showed that these materials were completely non cytotoxic to cellular viability. 
These results show that this novel nanostructure biomaterial has a great potential to be use in 
biomedical applications where NO has a therapeutical effect.  
1.  Introduction  
Nitric oxide (NO) is an endogenous free radical that plays a key role in the regulation of several 
physiological processes, such as the control of vasodilation, platelet interaction with the vessel wall, 
immune responses, wound healing and cellular communication [1-5]. The endogenous synthesis of 
NO is mediated through nitric oxide synthase (NOS) which catalyzes the conversion of L-arginine to 
NO and citrulline. At low concentrations, NO is quite stable and minimally reactive, however, at 
higher concentrations NO can interact with transition metals, heme-containing proteins, thiol groups 
leading to oxidation of functional groups on RNA, DNA and proteins [6]. The biological actions of 
NO have been shown to be dependent on its site and source of production, as well as its concentration.  
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Due to the multifaceted role of NO in vivo, there is a great interest on the developing of NO 
releasing molecular systems for biomedical applications, especially to treat important diseases [7]. In 
this context, many different classes of NO donors have been prepared and applied in biological 
systems [8]. Some studies suggested that cysteine thiols (RSHs) of bioactive peptides such as 
glutathione (GSH), the most abundant non-protein thiol found in vivo, act as NO carriers and donors in 
tissues [9]. Thiols are directly involved in the metabolism and mobilization of NO, and GSH forms  
S-nitrosoglutathione (GSNO) in vivo [10], which belongs to a class of compounds named S-
nitrosothiols (RSNOs). GSNO and others RSNOs exhibit NO-like activities such as the inhibition of 
platelet adhesion, vasodilation, microbicidal actions, and wound healing [1,2,4,5,11,12]. However, the 
potential pharmacological applications of RSNOs, and in particular GSNO, require a vehicle since 
RSNOs are considered unstable in aqueous solution [9].  
A promising approach that has been considered to promote the uses of RSNOs as NO donors in 
biomedical applications is either the direct incorporation of NO donors, such as RSNOs, into 
biopolymers or nanoparticles [7,13-15]. In both cases, NO can be released directed to the target site 
for prolonged periods of time and exerts its therapeutic effects, such as the promotion of cutaneous 
wound healing and dermal vasodilation, upon application in vivo [1,2,4,5]. 
However, a crucial issue with regards to propose the clinical uses of NO-releasing materials is the 
evaluation of the cytotoxicity of the NO donor molecules (RSNOs) and RSNOs-loaded to the 
polymers. It was reported that GSNO decreased neutrophil viability in a time and concentration-
dependent manner, while GSH exposure alone did not enhance cell death or DNA fragmentation at 
any concentration studied, as assessed by a fluorescent viability/cytotoxicity assay [16].  
In this work the tri-peptide GSH, precursor of the NO donor GSNO, was encapsulated into a 
mucoadhesive combination of alginate/chitosan. GSH-encapsulated alginate/chitosan nanoparticles 
were characterized, and the thiol was nitrosated to form encapsulated GSNO. The kinetics of NO 
release from GSNO-containing alginate/chitosan nanoparticles were monitored at physiological 
temperature, and compared to free GSNO. Finally, the cytotoxicity of either GSH- or GSNO-
encapsulated were evaluated. The results showed that encapsulated GSH can be nitrosated to form 
GSNO-containing nanoparticles. The results suggest that this formulation is a potent candidate for 
pharmacological applications that require the release of controlled amounts of NO for prolonged 
periods of time, where NO can have its physiological actions, without severe side effects.  
2.  Methods  
2.1.  Preparation of polymeric nanoparticles with GSH 
The alginate/chitosan nanoparticles containing GSH were prepared thorough ionic gelation 
method [17]. Briefly, it was prepared an aqueous chitosan solution (1.33%) with GSH. A ratio of 
alginate/chitosan solutions of 0.75 was obtained by dropping wise previous prepared chitosan aqueous 
solution into the alginate aqueous solution (0.005 g/100 mL) (pH 4.0), under magnetic stirring. 
2.2.  Characterization, encapsulation efficiency and physical stability of the alginate/chitosan 
nanoparticles 
The average particle size (number average size) and size distribution of prepared nanoparticles as the 
zeta potential of alginate/chitosan ratio (0.75) were measured by photon correlation spectroscopy 
(PCS) (Nano ZS Zetasizer, Malvern Instruments Corp). The encapsulation efficiency of GSH in 
nanoparticles was determined by DTNB titration after ultrafiltration of the nanoparticles solution [12] 
The physical stability alginate/chitosan nanoparticles at 0.75 ratio was monitored over 37 days at 4°C, 
by measuring the average particles sizes and surface charges, as described previously.   
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2.3.  Nitrosation of GSH encapsulated in alginate/chitosan nanoparticles 
GSH (400 M) encapsulated in alginate/chitosan nanoparticles at ratio 0.75 and free GSH (400 M) 
were nitrosated by adding equimolar amounts of sodium nitrite directly into polymeric aqueous 
solution (pH 4.0) at 336 nm (  = 940 mol/L/cm), using an UV-Vis spectrophotometer [12]. 
2.4.  Kinetic measurements of NO release from encapsulated GSNO and free GSNO  
The kinetic curves of GSNO (400 M) decomposition with NO release were monitored for free GSNO 
(GSNO in aqueous solution) and encapsulated GSNO in alginate/chitosan nanoparticles from the 
absorption changes at 336 nm.  
2.5.  Cytotoxicity of GSH and GSNO free and encapsulated in nanoparticles 
The cytotoxicity of GSH and GSNO, free and encapsulated in alginate/chitosan nanoparticles, was 
assessed in a permanent lung fibroblast cell line (V79) culture derived from Chinese hamster [18]. 
These cells are commonly used for cytotoxicity studies [19]. The cells were plated at a density of 
3 x 10
4
 cells/ml in 96-well plates. Forty-eight hours after cell seeding, semiconfluent cultures were 
exposed to free GSH, free GSNO, encapsulated GSH and encapsulated GSNO, at different 
concentrations (0 – 18 μM). The cells were exposed for 24 h to the test medium with or without the 
compounds studied (control). Each concentration was tested in six replicates in each of three separate 
experiments. At the end of the incubation, two independent endpoints tests for cytotoxicity 
(Methylthiazoletetrazolium reduction- MTT and neutral red uptake were evaluated [20,21].  
3.  Results and Discussion 
3.1.  Preparation and characterization of GSH-containing alginate/chitosan nanoparticles  
Preparation of alginate/chitosan nanoparticles at ratio of 0.75, with and without GSH, showed average 
particles sizes of 361 and 301 nm, respectively, and positive surface charges with average values of 
+27 (with GSH) and + 22 mV (without GSH) (Table 1). Alginate/chitosan nanoparticles prepared 
showed the encapsulation efficiency of 27% (Table 1). These positively charged particles exhibited 
high stability after 37 days. 
Table 1. Particles sizes, surface charge (Zeta potential), and encapsulation efficiency of 
alginate/chitosan nanoparticles. 
Alginate/Chitosan 
ratios 
GSH 
(mg) 
Zeta 
Potential 
(mV) 
Particle sizes 
(nm) 
PdI Encapsulation 
efficiency (%) 
0.75 0 +22 301 0.316 --- 
0.75 5 +27 361 0.330 27 
3.2.  Nitrosation of GSH-encapsulated in alginate/chitosan nanoparticles 
GSH encapsulated in nanoparticles of alginate/chitosan was directly nitrosated by reacting with 
equimolar amount of sodium nitrite at pH 4.0. The formation of GSNO was confirmed by the 
detection of the characteristic GSNO absorption band at 336 nm ( * transition) (data not shown). 
Thus, a NO-donor molecule (GSNO) could be prepared directly in alginate/chitosan suspension by 
directly nitrosation of encapsulated GSH in the nanoparticles. 
3.3.  Kinetics of GSNO decomposition with NO release from free GSNO and encapsulated GSNO in 
polymeric nanoparticles 
The kinetic data of GSNO decomposition with NO release at 37°C for free GSNO, which corresponds 
to aqueous solution of GSNO (400 M) at pH 4.0 and GSNO (400 M) encapsulated in 
alginate/chitosan nanoparticles (alginate/chitosan ratio 0.75) at pH 4.0 were analyzed. The decrease of 
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the intensity of the absorption band at 336 nm is assigned to the homolytic cleavage of the S-N bond, 
with GSNO decomposition leading to the release of NO and the formation of oxidized glutathione [9]. 
Either free GSNO or encapsulated were able to spontaneously decomposes, releasing NO, under 
physiological temperature, for hours. However, for the first 3 h of the kinetic, the GSNO encapsulate 
in the nanoparticles can be considered stable (no change in the absorption at 336 nm). Only after 3 h of 
the kinetic, it was observed an increase in the rate of decomposition of encapsulated GSNO, with NO 
release. On the other side, the rate of free GSNO decomposition was observed to be continuously and 
linear from time zero to 7 h. Indeed, the rate of encapsulated GSNO decomposition was found to be 
1.2 x 10
-2
  0.2 x10
-2
 h
-1
 for 3 to 7 h. On the other hand, the rate of free GSNO decomposition was 
found to be 1.5 x 10
-2
  0.2 x 10
-2
 h
-1
 for 0 to 7 h. Therefore, encapsulation of GSNO in 
alginate/chitosan nanoparticles was responsible to decrease the rate of NO release, especially during 
the initial hours. This delay on the NO release may be due to the low diffusion rates of GSNO from 
the nanoparticles to the solution. 
3.4.  Cytotoxicity of free GSH, free GSNO and GSNO and GSH encapsulated in alginate/chitosan 
nanoparticles 
Free glutathione showed to be non cytotoxic to fibroblast V79 cells in the lysosomal (Neutral red) and 
slightly cytotoxic to mitochondrial (MTT) assays (15-20% around to 10 μM concentration), as is 
observed in Figure 1A. In the Figure 1B is shown that cytotoxicity in the case of GSNO was also not 
cytotoxic to fibroblast V79 cells in the lysosomal (Neutral red) and slightly cytotoxic to mitochondrial 
(MTT) assays (20% around to 16 μM concentration), as is observed in Figure 1B. 
Alginate/chitosan nanoparticles with or without GSH or GSNO exhibited non cytotoxicity (till 
18 μM concentration). 
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Figure 1. Viability graph in V79 cells with the cellular targets as MTT and NR of the free GSH (A) 
and free GSNO (B). 
4.  Conclusions 
The kinetic of NO release from free GSNO compared with GSNO-encapsulate in alginate/chitosan 
reveled that the encapsulation of the NO donor resulted in a thermal and hydrolytic protection of 
GSNO leading to an enhancement of NO activity by a controlled and sustained NO release from this 
new biomaterial. The higher stability of encapsulated GSNO, compared to free GSNO enable the use 
of GSNO in pharmaceutical applications, such as wound healing, or others uses where the biological 
effects of NO are required. 
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